Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT02998762 Completed - Clinical trials for Major Depressive Disorder

Long-Term Follow Up Study

CAN-BIND LTFU
Start date: February 3, 2016
Phase:
Study type: Observational

The LTFU study will conduct a naturalistic follow up of the well characterized CAN-BIND study population of patients every six months and continuing over a five-year period. This will provide information on the longitudinal progress in mood, functioning, and quality of life of the CAN-BIND sample with a view towards long-term outcome and treatment.

NCT ID: NCT02992158 Completed - Clinical trials for Major Depressive Disorder

Feasibility of a Behavioral Activation Trial

Start date: March 2016
Phase: N/A
Study type: Interventional

The goal of this project is to train community mental health therapists in behavioral activation (BA) treatment for major depressive disorder and then to conduct a study examining the feasibility of evaluating the effectiveness of BA in this setting.

NCT ID: NCT02983838 Recruiting - Clinical trials for Major Depressive Disorder

Research on Pathophysiology and Treatment in Depression Using Brain Derived Neurotrophic Factor and Amyloid Neuroimaging

Start date: April 2016
Phase: N/A
Study type: Observational [Patient Registry]

Target of the research Based on change of Brain-derived neurotrophic factor and other pro-inflammatory cytokine along with symptom improvement following treatment, the investigators are trying to find the new treatment target molecule. The investigators will follow up the subjective and objective cognitive dysfunction with psychiatric symptom profiles and compare the neuroimaging related to these change.

NCT ID: NCT02980484 Terminated - Clinical trials for Major Depressive Disorder

fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI

Start date: August 2016
Phase: Phase 2
Study type: Interventional

This pilot study aims to investigate the efficacy of fMRI-targeted repetitive transcranial magnetic stimulation (rTMS) in treatment of major depression associated with traumatic brain injury (TBI). Half of patients will receive active treatment, while the other will receive a sham treatment with the option of receiving open-label active treatment afterwards.

NCT ID: NCT02972632 Completed - Clinical trials for Major Depressive Disorder

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Start date: December 22, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).

NCT ID: NCT02960763 Completed - Clinical trials for Major Depressive Disorder

Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

OPTIMUM
Start date: February 24, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).

NCT ID: NCT02959502 Active, not recruiting - Clinical trials for Major Depressive Disorder

Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression

Start date: October 31, 2016
Phase: N/A
Study type: Interventional

The overall goals of this project are to assess the feasibility and impact of designing and implementing an at-home intervention aimed at preventing long-term cognitive decline and improving cognition in individuals currently at-risk for developing AD.

NCT ID: NCT02959307 Completed - Depression Clinical Trials

Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)

ELATED-3
Start date: November 2016
Phase: N/A
Study type: Interventional

Transcranial Light Therapy involves non-invasive and invisible beams of light that increase energy metabolism in the brain. Transcranial light therapy has been found to promote brain metabolism which may help people with depression. The research team proposes a novel approach to treating depression by using transcranial light therapy.

NCT ID: NCT02948036 Completed - Clinical trials for Major Depressive Disorder

A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

Specific Aim 1: Finalize development of the closed-loop strategy in the MMT application. Specific Aim 2: Evaluate the acceptability and feasibility of the MMT application with the target population to prepare for a large-scale efficacy trial.

NCT ID: NCT02943096 Terminated - Depression Clinical Trials

Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression

Flavanol
Start date: November 2016
Phase: N/A
Study type: Interventional

The goal of this proposal is to conduct the first pilot study of whether consuming flavanol supplements will augment the cognitive and mood benefits of antidepressant medication in older adults with Late LifeDepression (LLD). Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa. Currently available treatments for LLD (i.e., antidepressant medication) are limited in efficacy, especially in individuals who also suffer from cognitive impairment. Recent studies performed at Columbia and elsewhere suggest that flavanols may induce beneficial brain changes that support cognitive functioning and elevate mood, but their precise clinical effects in older adults with combined depression and cognitive impairment remain to be evaluated. For this study, the investigators plan to recruit 50 adults aged ≥60 years who have Major Depressive Disorder, meet a minimum depressive symptom threshold despite currently receiving an adequate trial of an antidepressant, and have a significant cognitive complaints without a diagnosis of dementia. Subjects will be randomized to receive 8 weeks of augmentation treatment with flavanol capsules (in addition to continuing their antidepressant) vs. capsules not containing flavanols. Pre- and post-treatment MRI scanning of the brain will be conducted, and comprehensive pre- and post-treatment neuropsychological assessment will be performed. Results from this project will allow the investigators to evaluate a novel therapeutic approach to LLD, which could have large public health ramifications given the prevalence, frequent treatment resistance, and chronicity characteristic of LLD.